Spikevax — The FDA granted full approval to Moderna’s COVID-19 vaccine, marketed under the brand name Spikevax, for adults Jan. 31.
Vabysmo — On Jan. 28, the FDA approved Roche’s faricimab-svoa, which goes by the brand name Vabysmo, to treat neovascular (wet) aged-related macular degeneration and diabetic macular edema, two leading causes of vision loss.
Kimmtrak — Tebentafusp-tebn, which goes by the brand name Kimmtrak, was approved Jan. 25 to treat unresectable or metastatic uveal melanoma.
Cibinqo — The FDA on Jan. 14 approved Pfizer’s abrocitinib, which goes by the brand name Cibinqo, for adults with moderate to severe atopic dermatitis, or eczema.
Quviviq — Daridorexant, which goes by the brand name Quviviq, was approved on Jan. 7 to treat adults with insomnia.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
